Study demonstrates efficacy of StatSeal® Advanced Plus Disc use for groin closure following atrial fibrillation ablation procedures to treat patients with irregular heartbeats.
Read Press ReleaseThe agreement will drive the discovery of more effective treatments for cardiovascular disease and development of safer drugs with the preclinical implementation of advanced human heart models
Read Press ReleaseModern Heart and Vascular Institute is proud to offer an intensive cardiac rehabilitation program designed to help patients get back to their normal lives after being diagnosed with cardiovascular disease.
Read Press ReleaseRecardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with Recardio's pivotal Heal-MI Phase 3 trial design with Dutogliptin in Acute Myocardial Infarction.
Read Press ReleaseRicardo Bellera, MD, joins Modern Heart and Vascular to provide quality heart and vascular care for adults living and working in The Woodlands, Katy, Humble, and greater Houston, Texas, area
Read Press ReleaseThe NIVA|HF investigational algorithm uses proprietary venous waveform technology from VoluMetrix to assess otherwise hard-to-obtain cardiovascular metrics. According to study authors, 'This non-invasive measurement has potential for … prevention of hospital admission in heart failure patients.'
Read Press ReleasePercy Francisco Morales, MD, joins Modern Heart and Vascular to provide excellent heart health services for adults living and working in Houston, TX, and the surrounding areas.
Read Press ReleaseAccumed Radial is pleased to announce renowned entrepreneur and venture capitalist William (Bill) N. Starling has become an investor and joined the Accumed Radial Board of Directors.
Read Press ReleaseInterventional Cardiology Review (ICR) journal names Dr Peter O'Kane as ICR's new Editor-in-Chief. Dr O'Kane's term begins July 26, 2021.
Read Press ReleaseNIVA|HF is an investigational device designed to monitor the venous waveform, a novel physiologic signal, in heart failure patients. As a Breakthrough Device, NIVA|HF will receive pre-market developmental assistance and prioritized regulatory review from FDA. NIVA|HF is the first application of VoluMetrix's proprietary venous waveform technology.
Read Press Release